Jpmorgan Chase & CO Pulmonx Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUNG
# of Institutions
118Shares Held
30.6MCall Options Held
400Put Options Held
0-
Primecap Management CO Pasadena, CA5.71MShares$40.7 Million0.03% of portfolio
-
Morgan Stanley New York, NY3.47MShares$24.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$19 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.18MShares$15.5 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.29MShares$9.21 Million0.0% of portfolio
About Pulmonx Corp
- Ticker LUNG
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 37,268,400
- Market Cap $265M
- Description
- Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...